Negin Mahmoudi Hamidabad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Negin Mahmoudi Hamidabad has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Amir Lerman
Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN
3 shared publications - Anita M. Kelsey
Division of Cardiology and Duke Heart Center, Duke University Medical Center, Durham, England
2 shared publications - Anita Sadeghpour
Cardiovascular Core Labs, MedStar Health, Georgetown University
2 shared publications - Azin Alizadehasl
Cardio‐Oncology Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran
2 shared publications - Homa Mazaherinia
Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Cardiologist, Tehran, Iran
2 shared publications - Khashayar Farnoud
Liver Transplantation Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Elsevier in Mayo Clinic Proceedings
Long-Term Cardiovascular Risk After Carotid Endarterectomy: Limited Insight From Traditional Risk Factors
- 22 April 2026
- Published by Elsevier in Mayo Clinic Proceedings
Open AccessLong-Term Cardiovascular Risk After Carotid Endarterectomy: Limited Insight From Traditional Risk Factors
- Open Access
- 6 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0341111
Gut microbiome compositional clusters in association with cardiovascular risk: An observational cohort study
Aims: The gut microbiome (GM) is increasingly recognized for its role in atherosclerosis development. However, its potential as a biomarker for risk-stratification in patients with atherosclerotic cardiovascular (CV) comorbidities remains under-explored. This study aimed to identify distinct GM clusters associated with elevated CV risk. Methods: In this prospective observational cohort, patients with coronary artery disease, hypertension, hyperlipidemia, or diabetes mellitus referring to Mayo Clinic from 2013 to 2018 were enrolled. Bacterial DNA was analyzed in the V3-V5 region of 16S rDNA. Beta-diversity was plotted using Principal Coordinates Analysis. Unsupervised hierarchical clustering of the GM classified participants into two clusters. Cox regression evaluated the association between clusters and Major Adverse Cardiac Events (MACE), defined as a composite of cardiac events, heart failure, and all-cause mortality. Permutational Multivariate Analysis of Variance identified clinical factors contributing to cluster assignment. Linear Discriminant analysis identified GM taxa with differential abundance among clusters and their effect sizes. Results: Among 211 participants (median age 60 [IQR: 50–70] years; 57.3% male), two distinct GM profiles emerged (Cluster H: N = 104; Cluster L: N = 107, P < 0.001). Cluster L participants were younger (P < 0.001), more likely female (P = 0.009), and had healthier CV profiles, including lower BMI (P = 0.007), hypertension (P = 0.010), hyperlipidemia (P = 0.005), and lower coronary artery disease prevalence (P = 0.003). Over a median follow-up of 7.4 years, Cluster L had a significantly lower incidence of MACE compared to Cluster H (HR = 0.48, 95% CI: 0.26–0.91, P = 0.024). Cluster L had higher operational taxonomic units (P < 0.001) and lower Bacillota-to-Bacteroidetes ratio (P < 0.001) compared to Cluster H. The predominant taxa in Cluster L included Bacteroides , Alistipes , and Parabacteroides , whereas Blautia , Agathobacter , and Clostridium sensu stricto-1 were more abundant in Cluster H. Conclusion: Distinct GM profiles are associated with varying CV risk, highlighting the potential of unsupervised GM profiling as a novel tool for risk stratification and individualized therapy.
- 6 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0341111
Open AccessGut microbiome compositional clusters in association with cardiovascular risk: An observational cohort study
Aims: The gut microbiome (GM) is increasingly recognized for its role in atherosclerosis development. However, its potential as a biomarker for risk-stratification in patients with atherosclerotic cardiovascular (CV) comorbidities remains under-explored. This study aimed to identify distinct GM clusters associated with elevated CV risk. Methods: In this prospective observational cohort, patients with coronary artery disease, hypertension, hyperlipidemia, or diabetes mellitus referring to Mayo Clinic from 2013 to 2018 were enrolled. Bacterial DNA was analyzed in the V3-V5 region of 16S rDNA. Beta-diversity was plotted using Principal Coordinates Analysis. Unsupervised hierarchical clustering of the GM classified participants into two clusters. Cox regression evaluated the association between clusters and Major Adverse Cardiac Events (MACE), defined as a composite of cardiac events, heart failure, and all-cause mortality. Permutational Multivariate Analysis of Variance identified clinical factors contributing to cluster assignment. Linear Discriminant analysis identified GM taxa with differential abundance among clusters and their effect sizes. Results: Among 211 participants (median age 60 [IQR: 50–70] years; 57.3% male), two distinct GM profiles emerged (Cluster H: N = 104; Cluster L: N = 107, P < 0.001). Cluster L participants were younger (P < 0.001), more likely female (P = 0.009), and had healthier CV profiles, including lower BMI (P = 0.007), hypertension (P = 0.010), hyperlipidemia (P = 0.005), and lower coronary artery disease prevalence (P = 0.003). Over a median follow-up of 7.4 years, Cluster L had a significantly lower incidence of MACE compared to Cluster H (HR = 0.48, 95% CI: 0.26–0.91, P = 0.024). Cluster L had higher operational taxonomic units (P < 0.001) and lower Bacillota-to-Bacteroidetes ratio (P < 0.001) compared to Cluster H. The predominant taxa in Cluster L included Bacteroides , Alistipes , and Parabacteroides , whereas Blautia , Agathobacter , and Clostridium sensu stricto-1 were more abundant in Cluster H. Conclusion: Distinct GM profiles are associated with varying CV risk, highlighting the potential of unsupervised GM profiling as a novel tool for risk stratification and individualized therapy.
- Open Access
- 6 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (15) , e035000
Prognostic Implications of Resistive Reserve Ratio in Patients With Nonobstructive Coronary Artery Disease With Myocardial Bridging
Background: Myocardial bridging (MB) is accompanied by the dynamic extravascular compression of epicardial coronary arteries, leading to intracoronary hemodynamic disturbance with abnormal coronary flow profiles. We aimed to evaluate the prognostic implications of resistive reserve ratio (RRR), a composite measure of flow and pressure parameters that represents the vasodilatory capacity of the coronary arteries, in patients with angina with nonobstructive coronary artery disease (ANOCA) and MB, in comparison with coronary flow reserve (CFR). Methods and Results: In this retrospective cohort study, we included patients with ANOCA who underwent coronary reactivity testing, where MB was identified by transient constriction in coronary artery segments between systole and diastole. Abnormal CFR and RRR were defined as P =0.144 and P =0.398, respectively). Over a median follow‐up time of 6.9 years, abnormal RRR predicted major adverse cardiac events in patients with MB (hazard ratio [HR], 4.38 [95% CI, 1.71–11.21]; P =0.002) and without MB (HR, 1.91 [95% CI, 1.38–2.64]; P P P =0.073). Conclusions: In patients with ANOCA and MB, impaired RRR was superior to impaired CFR in distinguishing patients at a higher risk of future adverse events, suggesting that RRR may serve as a risk stratification tool in patients with MB and ANOCA.
- 6 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (15) , e035000
Open AccessPrognostic Implications of Resistive Reserve Ratio in Patients With Nonobstructive Coronary Artery Disease With Myocardial Bridging
Background: Myocardial bridging (MB) is accompanied by the dynamic extravascular compression of epicardial coronary arteries, leading to intracoronary hemodynamic disturbance with abnormal coronary flow profiles. We aimed to evaluate the prognostic implications of resistive reserve ratio (RRR), a composite measure of flow and pressure parameters that represents the vasodilatory capacity of the coronary arteries, in patients with angina with nonobstructive coronary artery disease (ANOCA) and MB, in comparison with coronary flow reserve (CFR). Methods and Results: In this retrospective cohort study, we included patients with ANOCA who underwent coronary reactivity testing, where MB was identified by transient constriction in coronary artery segments between systole and diastole. Abnormal CFR and RRR were defined as P =0.144 and P =0.398, respectively). Over a median follow‐up time of 6.9 years, abnormal RRR predicted major adverse cardiac events in patients with MB (hazard ratio [HR], 4.38 [95% CI, 1.71–11.21]; P =0.002) and without MB (HR, 1.91 [95% CI, 1.38–2.64]; P P P =0.073). Conclusions: In patients with ANOCA and MB, impaired RRR was superior to impaired CFR in distinguishing patients at a higher risk of future adverse events, suggesting that RRR may serve as a risk stratification tool in patients with MB and ANOCA.
- Open Access
- 18 June 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-8
Impact of commissural calcification on clinical outcome of percutaneous balloon mitral valvuloplasty; a retrospective cohort study of 876 patients
Background: Percutaneous balloon mitral valvuloplasty (PBMV) is the ACC/AHA class I recommendation for treating symptomatic rheumatic mitral stenosis with suitable valve morphology, less than moderate MR and absence of left atrium clot. The mitral valve restenosis and significant mitral regurgitation (MR) are known adverse outcomes of PBMV. This study aimed to evaluate the outcomes of PBMV in patients with severe mitral stenosis and the effect of Commissural Calcification (CC) on the outcomes.Methods: In this single-center retrospective cohort study, 876 patients who underwent PBMV were categorized into three groups based on their Wilkins score (Group I: score ≤ 8, Group II: score 9–10, and Group III: score 11–12). Patients were evaluated before, early after PBMV and at 6- and 24-month follow-ups. Main clinical outcomes were defined as significant restenosis and or symptomatic significant MR (moderate to severe and severe MR) or candidate for mitral valve replacement (MVR). The outcomes were compared between patients with and without CC.Results: A total of 876 patients with mean age 46.4 ± 12.3 years (81.0% females) were categorized based on Wilkins score. 333 (38.0%) were in Group I, 501 (57.2%) were in Group II, and 42 (4.8%) were in Group III. CC was present in 175 (20.0%) of the patients, among whom 95 (54.3%) had calcification of the anterolateral commissure, 64 (36.6%) had calcification of the posteromedial commissure, and in 16 (9.1%) patients both commissures were calcified. There was a significant difference in Wilkins score between patients with and without CC (P < 0.001). CC was associated with higher odds of significant symptomatic MR at early and mid-term follow up (OR: 1.69, 95%CI 1.19–2.41,P = 0.003; and OR: 3.90, 95%CI 2.61–5.83,P < 0.001, respectively), but not with restenosis (P = 0.128). Wilkins Groups II and III did not show higher odds of significant symptomatic MR compared to Group I at early (II:P = 0.784; III:P = 0.098) and mid-term follow up (II:P = 0.216; III:P = 0.227). Patients in Wilkins Group II had higher odds of restenosis compared to Group I (OR: 2.96,95%CI: 1.35–6.27,P = 0.007).Conclusion: Commissural calcification (CC) is an independent predictor of the significant symptomatic MR (an important determinant of adverse outcome) following PBMV in the early and mid-term follow-up. Mitral valve restenosis occurs more in patients with higher Wilkins score compared to group I with score ≤ 8. Combined Wilkins score and CC should be considered for patient suitability for PBMV.
- 18 June 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-8
Open AccessImpact of commissural calcification on clinical outcome of percutaneous balloon mitral valvuloplasty; a retrospective cohort study of 876 patients
Background: Percutaneous balloon mitral valvuloplasty (PBMV) is the ACC/AHA class I recommendation for treating symptomatic rheumatic mitral stenosis with suitable valve morphology, less than moderate MR and absence of left atrium clot. The mitral valve restenosis and significant mitral regurgitation (MR) are known adverse outcomes of PBMV. This study aimed to evaluate the outcomes of PBMV in patients with severe mitral stenosis and the effect of Commissural Calcification (CC) on the outcomes.Methods: In this single-center retrospective cohort study, 876 patients who underwent PBMV were categorized into three groups based on their Wilkins score (Group I: score ≤ 8, Group II: score 9–10, and Group III: score 11–12). Patients were evaluated before, early after PBMV and at 6- and 24-month follow-ups. Main clinical outcomes were defined as significant restenosis and or symptomatic significant MR (moderate to severe and severe MR) or candidate for mitral valve replacement (MVR). The outcomes were compared between patients with and without CC.Results: A total of 876 patients with mean age 46.4 ± 12.3 years (81.0% females) were categorized based on Wilkins score. 333 (38.0%) were in Group I, 501 (57.2%) were in Group II, and 42 (4.8%) were in Group III. CC was present in 175 (20.0%) of the patients, among whom 95 (54.3%) had calcification of the anterolateral commissure, 64 (36.6%) had calcification of the posteromedial commissure, and in 16 (9.1%) patients both commissures were calcified. There was a significant difference in Wilkins score between patients with and without CC (P < 0.001). CC was associated with higher odds of significant symptomatic MR at early and mid-term follow up (OR: 1.69, 95%CI 1.19–2.41,P = 0.003; and OR: 3.90, 95%CI 2.61–5.83,P < 0.001, respectively), but not with restenosis (P = 0.128). Wilkins Groups II and III did not show higher odds of significant symptomatic MR compared to Group I at early (II:P = 0.784; III:P = 0.098) and mid-term follow up (II:P = 0.216; III:P = 0.227). Patients in Wilkins Group II had higher odds of restenosis compared to Group I (OR: 2.96,95%CI: 1.35–6.27,P = 0.007).Conclusion: Commissural calcification (CC) is an independent predictor of the significant symptomatic MR (an important determinant of adverse outcome) following PBMV in the early and mid-term follow-up. Mitral valve restenosis occurs more in patients with higher Wilkins score compared to group I with score ≤ 8. Combined Wilkins score and CC should be considered for patient suitability for PBMV.
- Open Access
- 1 September 2023
- Published by Taylor & Francis in Breast Cancer Management
- Vol. 12 (3)
Survival Analysis of Breast Cancer in Patients with HER2/neu+, ER-, PR-: a Retrospective Cohort Study
Aim: We aimed to study the characteristics of the breast cancer patients with positive HER2/neu+, ER- and PR- receptors. Methods: 119 patients with breast cancer were included in this retrospective...
- 1 September 2023
- Published by Taylor & Francis in Breast Cancer Management
- Vol. 12 (3)
Open AccessSurvival Analysis of Breast Cancer in Patients with HER2/neu+, ER-, PR-: a Retrospective Cohort Study
Aim: We aimed to study the characteristics of the breast cancer patients with positive HER2/neu+, ER- and PR- receptors. Methods: 119 patients with breast cancer were included in this retrospective...
- Open Access
- 7 October 2022
- Published by SAGE Publications in Clinical Medicine Insights: Case Reports
- Vol. 15
Mild Facial Paresis in a Recipient of Gam-COVID-Vac Vaccine: A Case Report
Facial paralysis has been reported as a rare side effect of mRNA COVID-19 vaccines. The Gam-COVID-Vac was introduced in August 2020 in Russia. There was no report of facial paralysis in phase I to III clinical trials of the vaccine. To our knowledge, there is no post-marketing report of facial paresis with Gam-COVID-Vac vaccination to this date. The Gam-COVID-Vac vaccine has a reported efficacy of 90%, but its safety and efficacy have not been approved by international organizations to this date. Iran is among the countries using the Gam-COVID-Vac vaccine. Here, we present a case of mild facial paresis that occurred shortly after the Gam-COVID-Vac vaccine administration in a female healthcare worker.
- 7 October 2022
- Published by SAGE Publications in Clinical Medicine Insights: Case Reports
- Vol. 15
Open AccessMild Facial Paresis in a Recipient of Gam-COVID-Vac Vaccine: A Case Report
Facial paralysis has been reported as a rare side effect of mRNA COVID-19 vaccines. The Gam-COVID-Vac was introduced in August 2020 in Russia. There was no report of facial paralysis in phase I to III clinical trials of the vaccine. To our knowledge, there is no post-marketing report of facial paresis with Gam-COVID-Vac vaccination to this date. The Gam-COVID-Vac vaccine has a reported efficacy of 90%, but its safety and efficacy have not been approved by international organizations to this date. Iran is among the countries using the Gam-COVID-Vac vaccine. Here, we present a case of mild facial paresis that occurred shortly after the Gam-COVID-Vac vaccine administration in a female healthcare worker.
- Open Access
- 14 September 2022
- Published by Springer Nature in Research Square
Effect of Commissural Calcification on Clinical Outcomes of Percutaneous Mitral Valvuloplasty
Background Percutaneous mitral valvuloplasty (PMV) is a safe and widely used treatment in patients with symptomatic rheumatic mitral stenosis. This study aimed to evaluate short-term and mid-term outcomes of PMV in patients with severe mitral stenosis and the effect of commissural calcifications on the outcomes. Methods Medical records of 961 patients after PMV were reviewed. All patients were evaluated using transthoracic echocardiography before and after 24 hours. Patients were divided into three subgroups based on their Wilkins score (group I: score ≤8, group II: score 9-10, and group III: score 11-12). Also, patients were divided into two subgroups based on the presence or absence of commissural calcification. Patients were evaluated before PMV, 24 hours after the procedure and were followed for 6 and 24 months to evaluate the short-term and mid-term outcomes. The echocardiographic measures (mitral valve area, indexed mitral valve index, mitral valve mean gradient, and pulmonary artery systolic pressure) were compared after PMV, and at 6 months and 24 month follow-ups. Main clinical outcomes (moderate and severe mitral regurgitation and restenosis) were compared between patients with and without commissural calcifications. Results:Mean age of the patients was 46.6 ± 12.2, and 81.7 % of patients (n=785) were females. Groups I, II, and III (based on Wilkins score) consisted of 353 (36.7%), 559 (58.1%), and 49 (5%) patients, respectively. Mitral valve area (MVA) and indexed MVA increased significantly in all three groups; in both short-term and mid-term follow-ups (pmoderate MR) did not differ statistically between the three groups. Commissural calcification was present in 190 patients (19.77%). Restenosis was significantly higher in the presence of commissural calcification (pConclusion Both Wilkins score and presence of commissural calcification are associated with a higher incidence of mitral valve restenosis. While there is no strong association between higher Wilkins scores and higher rates of significant mitral regurgitation, commissural calcification is associated with a higher rate of severe mitral regurgitation.
- 14 September 2022
- Published by Springer Nature in Research Square
Open AccessEffect of Commissural Calcification on Clinical Outcomes of Percutaneous Mitral Valvuloplasty
Background Percutaneous mitral valvuloplasty (PMV) is a safe and widely used treatment in patients with symptomatic rheumatic mitral stenosis. This study aimed to evaluate short-term and mid-term outcomes of PMV in patients with severe mitral stenosis and the effect of commissural calcifications on the outcomes. Methods Medical records of 961 patients after PMV were reviewed. All patients were evaluated using transthoracic echocardiography before and after 24 hours. Patients were divided into three subgroups based on their Wilkins score (group I: score ≤8, group II: score 9-10, and group III: score 11-12). Also, patients were divided into two subgroups based on the presence or absence of commissural calcification. Patients were evaluated before PMV, 24 hours after the procedure and were followed for 6 and 24 months to evaluate the short-term and mid-term outcomes. The echocardiographic measures (mitral valve area, indexed mitral valve index, mitral valve mean gradient, and pulmonary artery systolic pressure) were compared after PMV, and at 6 months and 24 month follow-ups. Main clinical outcomes (moderate and severe mitral regurgitation and restenosis) were compared between patients with and without commissural calcifications. Results:Mean age of the patients was 46.6 ± 12.2, and 81.7 % of patients (n=785) were females. Groups I, II, and III (based on Wilkins score) consisted of 353 (36.7%), 559 (58.1%), and 49 (5%) patients, respectively. Mitral valve area (MVA) and indexed MVA increased significantly in all three groups; in both short-term and mid-term follow-ups (pmoderate MR) did not differ statistically between the three groups. Commissural calcification was present in 190 patients (19.77%). Restenosis was significantly higher in the presence of commissural calcification (pConclusion Both Wilkins score and presence of commissural calcification are associated with a higher incidence of mitral valve restenosis. While there is no strong association between higher Wilkins scores and higher rates of significant mitral regurgitation, commissural calcification is associated with a higher rate of severe mitral regurgitation.
- Open Access
- 12 July 2022
- Published by Springer Nature in Research Square
Mild Facial Paresis in a recipient of Gam-COVID-Vac Vaccine: A Case Report.
Facial paralysis has previously been reported as a rare side effect of vaccines such as influenza (1). Among COVID-19 vaccines, there have been reports of facial paralysis associated with BNT162 and 2019-nCoV Vaccine mRNA-1273 vaccines (2). To our knowledge, there is no report of facial paresis due to the Gam-COVID-Vac vaccination. Gam-COVID-Vac vaccine (rAd26 and rAd5 vector-based) was introduced in Russia in August 2020. In September 2020 the first peer-reviewed study of its I/II phase clinical trials was published and no serious side effects were reported (3). The results of the Gam-COVID-Vac phase III clinical trial also had no report of serious side effects (4). The Gam-COVID-Vac vaccine is reported to have above 90 percent efficacy, but still, there is no official report on its safety and efficacy by international organizations (5).Iran is among the countries using the Gam-COVID-Vac vaccine. Despite using this vaccine in many countries, there has been no official report of facial paresis/palsy in association with it. Here, we present a case of mild facial paresis that occurred shortly after Gam-COVID-Vac vaccine administration in a female healthcare worker.
- 12 July 2022
- Published by Springer Nature in Research Square
Open AccessMild Facial Paresis in a recipient of Gam-COVID-Vac Vaccine: A Case Report.
Facial paralysis has previously been reported as a rare side effect of vaccines such as influenza (1). Among COVID-19 vaccines, there have been reports of facial paralysis associated with BNT162 and 2019-nCoV Vaccine mRNA-1273 vaccines (2). To our knowledge, there is no report of facial paresis due to the Gam-COVID-Vac vaccination. Gam-COVID-Vac vaccine (rAd26 and rAd5 vector-based) was introduced in Russia in August 2020. In September 2020 the first peer-reviewed study of its I/II phase clinical trials was published and no serious side effects were reported (3). The results of the Gam-COVID-Vac phase III clinical trial also had no report of serious side effects (4). The Gam-COVID-Vac vaccine is reported to have above 90 percent efficacy, but still, there is no official report on its safety and efficacy by international organizations (5).Iran is among the countries using the Gam-COVID-Vac vaccine. Despite using this vaccine in many countries, there has been no official report of facial paresis/palsy in association with it. Here, we present a case of mild facial paresis that occurred shortly after Gam-COVID-Vac vaccine administration in a female healthcare worker.
- Open Access
- 7 July 2022
- Published by Springer Nature in Research Square
Guillain-Barré Syndrome in Association with COVID-19 Vaccination: A Systematic Review
Since the beginning of worldwide vaccination against coronavirus disease 2019 (COVID-19), studies have reported a possible association between vaccination and Guillain-Barré syndrome (GBS). In this regard, we conducted a systematic review assessing different demographic, clinical, and neurophysiological aspects of patients with GBS following immunization with COVID-19 vaccines. A comprehensive search of PubMed, Web of Science, Scopus, and Google Scholar was performed. Articles in English between January 2020 and November 2021 were included. Data on demographics, clinical characteristics, vaccines information, treatment approaches, and outcomes were extracted. The data of a total of 88 patients out of 41 studies was included. The mean age of patients was 58.7 ± 16.6 years and 55 cases (62.5%) were male. AstraZeneca was the most-reported vaccine associated with GBS with 52 cases (59.1%) followed by Pfizer with 20 cases (22.7%). GBS occurred after the first dose of vaccination in 70 cases (79.5%). The mean time interval between vaccination and symptom onset was 13.9 ± 7.4 days. Limb weakness (47.7%), sensory disturbance (38.6%), and facial weakness (27.3%) were the most common reported symptoms, respectively. Albuminocytologic dissociation was seen in 65% of patients who underwent lumbar puncture (n = 65). Acute inflammatory demyelinating polyradiculopathy was the most common GBS subtype, which was reported in 38 patients (43.2%). While one-fifth of patients underwent intubation (n = 17), a favorable outcome was achieved in the majority of subjects (n = 46, 63%). Overall, a small rise in GBS incidence, following various COVID-19 vaccines, was observed. Notably, 85% of affected individuals experienced at least a partial recovery.
- 7 July 2022
- Published by Springer Nature in Research Square
Open AccessGuillain-Barré Syndrome in Association with COVID-19 Vaccination: A Systematic Review
Since the beginning of worldwide vaccination against coronavirus disease 2019 (COVID-19), studies have reported a possible association between vaccination and Guillain-Barré syndrome (GBS). In this regard, we conducted a systematic review assessing different demographic, clinical, and neurophysiological aspects of patients with GBS following immunization with COVID-19 vaccines. A comprehensive search of PubMed, Web of Science, Scopus, and Google Scholar was performed. Articles in English between January 2020 and November 2021 were included. Data on demographics, clinical characteristics, vaccines information, treatment approaches, and outcomes were extracted. The data of a total of 88 patients out of 41 studies was included. The mean age of patients was 58.7 ± 16.6 years and 55 cases (62.5%) were male. AstraZeneca was the most-reported vaccine associated with GBS with 52 cases (59.1%) followed by Pfizer with 20 cases (22.7%). GBS occurred after the first dose of vaccination in 70 cases (79.5%). The mean time interval between vaccination and symptom onset was 13.9 ± 7.4 days. Limb weakness (47.7%), sensory disturbance (38.6%), and facial weakness (27.3%) were the most common reported symptoms, respectively. Albuminocytologic dissociation was seen in 65% of patients who underwent lumbar puncture (n = 65). Acute inflammatory demyelinating polyradiculopathy was the most common GBS subtype, which was reported in 38 patients (43.2%). While one-fifth of patients underwent intubation (n = 17), a favorable outcome was achieved in the majority of subjects (n = 46, 63%). Overall, a small rise in GBS incidence, following various COVID-19 vaccines, was observed. Notably, 85% of affected individuals experienced at least a partial recovery.
- 1 May 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 55, 225.e5-225.e6
Aseptic meningitis following AZD1222 COVID-19 vaccination
- 1 May 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 55, 225.e5-225.e6
Aseptic meningitis following AZD1222 COVID-19 vaccination